Key result
Clozapine use is linked to ~240% higher short-term perimyocarditis and increased long-term heart failure risk.
Why the study?
The risk of cardiac adverse events following clozapine use is debated and is unknown for the chemically related and widely used antipsychotics olanzapine and quetiapine.
Does exposure to clozapine, olanzapine, or quetiapine increase the risk of perimyocarditis or heart failure compared to no antipsychotic treatment?
Cohort (n=201,045)
Does exposure to clozapine, olanzapine, or quetiapine increase the risk of perimyocarditis or heart failure compared to no antipsychotic treatment?
Clozapine, but not olanzapine or quetiapine, is associated with a significantly increased risk of perimyocarditis within 2 months and heart failure within 3 years.
Answers are grounded in this paper and cite their sources.
May support cardiac monitoring with clozapine; leaves open causality and generalizability pending randomized trials.
The risk of cardiac adverse events following clozapine use is debated and is unknown for the chemically related and widely used antipsychotics olanzapine and quetiapine. National Swedish registers were used to identify all patients 16-75 years old with antipsychotic dispensations between 2005 and 2018. The short-term outcome was a diagnosis of perimyocarditis (pericarditis and/or myocarditis) within two months of first dispensation, and the long-term outcome was heart failure (including cardiomyopathy) within three years. Cox regressions with time varying exposure were used to estimate hazard rates (HR) and their 95% confidence intervals (CI). A total of 201,045 individuals were included in the cohort. The risk of developing perimyocarditis during clozapine treatment tripled compared to no antipsychotic treatment (HR 3.4, CI 1.6-7.3), although the absolute rate remained comparably low. The long-term risk of heart failure during clozapine treatment was also elevated (HR 1.3, CI 1.1-1.7). Treatment with either or both olanzapine or quetiapine was not associated with an increased relative risk of perimyocarditis, or heart failure compared to no antipsychotic treatment. Clozapine use is therefore associated with a substantially elevated short-term risk of perimyocarditis and an increased risk of heart failure within three years.
No takes yet. Share an insight, caveat, or question.
Clapham et al. (2023) conducted a cohort in Patients with antipsychotic dispensations (n=201,045). Clozapine vs. No antipsychotic treatment was evaluated on Perimyocarditis within two months (HR 3.4, 95% CI 1.6-7.3). Clozapine use tripled the short-term risk of perimyocarditis and increased the long-term risk of heart failure compared to no antipsychotic treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: